Pharmacokinetics of 1α,25-Dihydroxyvitamin D3 in Normal Mice after Systemic Exposure to Effective and Safe Antitumor Doses

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Oncology

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000076336
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo

  2004cited by this paper
• Pharmacokinetics of high‐dose oral calcitriol: Results from a phase 1 trial of calcitriol and paclitaxel

  2002cited by this paper
• Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis.

  2001cited by this paper
• A Phase I trial of pulse calcitriol in patients with refractory malignancies

  2001cited by this paper
• Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.

  2001cited by this paper
• 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo.

  1999cited by this paper
• A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy.

  1999cited by this paper
• Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone.

  1998cited by this paper
• Novel vitamin D3 analog (CB1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo.

  1998cited by this paper
• Pharmacokinetics and systemic effect on calcium homeostasis of 1α,24-dihydroxyvitamin D2 in rats comparison with 1α,25-Dihydroxyvitamin d2, calcitriol, and calcipotriol

  1997cited by this paper
• Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system.

  1997cited by this paper
• Antiproliferative effects in vitro and in vivo of 1,25-dihydroxyvitamin D3 and a vitamin D3 analog in a squamous cell carcinoma model system

  1995cited by this paper
• Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.

  1994cited by this paper
• Growth control of human colon cancer cells by vitamin D and calcium in vitro.

  1992cited by this paper
• 1,25-Dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20).

  1986cited by this paper
• Studies of the effect of 1,25-dihydroxycholecalciferol on the proliferation and differentiation of the human promyelocytic leukaemia cell line HL-60.

  1986cited by this paper
• 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture.

  1981cited by this paper
• Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

  1966cited by this paper

• VDR-Mediated Inhibition of Glycolysis and Metastasis by Calcitriol in Triple-Negative Breast Cancer

  2025cites this paper
• Calcitriol Protects against Acetaminophen-Induced Hepatotoxicity in Mice

  2023cites this paper
• Evaluation of In Vitro and In Vivo Antiviral Activities of Vitamin D for SARS-CoV-2 and Variants

  2023cites this paper
• Vitamin D Regulation of a SOD1-to-SOD2 Antioxidative Switch to Prevent Bone Cancer

  2020cites this paper
• Vitamin D Suppresses Ovarian Cancer Growth and Invasion by Targeting Long Non-Coding RNA CCAT2

  2020cites this paper
• Vitamin D Signaling in Inflammation and Cancer: Molecular Mechanisms and Therapeutic Implications

  2020cites this paper
• Vitamin D regulation of a SOD1-to-SOD2 antioxidative switch to prevent osteosarcoma transformation

  2020cites this paper
• Pharmacokinetic interaction of calcitriol with 20(S)‐protopanaxadiol in mice: Determined by LC/MS analysis

  2019influential citation
• Novel calcitriol analogue with an oxolane group: In vitro, in vivo, and in silico studies

  2019cites this paper
• Calcitriol and cancer therapy: A missed opportunity

  2018cites this paper
• Vitamin D in prostate cancer

  2018cites this paper
• Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions

  2016cites this paper
• Calcitriol and 20(S)-protopanaxadiol synergistically inhibit growth and induce apoptosis in human prostate cancer cells.

  2016cites this paper
• Vitamin D Enhances the Efficacy of Irinotecan through miR-627–Mediated Inhibition of Intratumoral Drug Metabolism

  2016cites this paper
• Vitamin D Receptor (VDR) and Cholesterol Homeostasis: Interplay of VDR Enzyme Targets and Vitamin D Deficiency

  2016cites this paper
• Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer

  2015cites this paper
• Vitamin D Analogue: Potent Antiproliferative Effects on Cancer Cell Lines and Lack of Hypercalcemic Activity

  2015cites this paper
• PKPD modelling to predict altered disposition of 1α,25‐dihydroxyvitamin D3 in mice due to dose‐dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation

  2015influential citation
• Inhibition of Mouse Breast Tumor-Initiating Cells by Calcitriol and Dietary Vitamin D

  2015cites this paper
• Vitamin D in cancer: effects of pharmaceutical drugs on the vitamin D pharmacokinetics

  2014cites this paper
• Role of the Vitamin D Receptor in MDR1/P-glycoprotein Regulation at the Blood-brain Barrier

  2014cites this paper
• Nitric oxide release from trigeminal satellite glial cells is attenuated by glial modulators and glutamate.

  2013cites this paper
• Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: importance of mammary CYP27B1 for treatment and prevention.

  2013cites this paper
• Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.

  2013cites this paper
• Vitamin D: Pharmacokinetics and Safety When Used in Conjunction with the Pharmaceutical Drugs Used in Cancer Patients: A Systematic Review

  2013cites this paper
• MicroRNA-627 mediates the epigenetic mechanisms of vitamin D to suppress proliferation of human colorectal cancer cells and growth of xenograft tumors in mice.

  2013cites this paper
• Comparative effects of 1α‐hydroxyvitamin D3 and 1,25‐dihydroxyvitamin D3 on transporters and enzymes in fxr(+/+) and fxr(‐/‐) mice

  2013cites this paper
• Vitamin D and cancer:present status and future prospects

  2013cites this paper
• MiR-627 mediates the epigenetic mechanisms of vitamin D in suppression of colon cancer growth

  2013cites this paper
• Inecalcitol, an analog of 1,25D₃, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system

  2013cites this paper
• Buthionine Sulfoximine and 1,25-Dihydroxyvitamin D Induce Apoptosis in Breast Cancer Cells via Induction of Reactive Oxygen Species

  2012cites this paper
• Inecalcitol, an analog of 1α,25(OH)2D3, induces growth arrest of androgen‐dependent prostate cancer cells

  2012cites this paper
• A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay.

  2012cites this paper
• Vitamin D and breast cancer: evidence for biological and clinical significance

  2012cites this paper
• bone fractures, may not be relevant for breast cancer outcomes. The optimal serum vitamin D level for breast cancer patients is unknown. Low serum level of vitamin D is associated with an increased risk of breast cancer in a

  2012cites this paper
• The role of vitamin D in cancer prevention and treatment.

  2012cites this paper
• EnhancedAnticancerActivity and Increased HypercalcemicToxicity in aMouseXenograft Modelof ProstateCancer

  2012cites this paper
• Dietary vitamin D₃ and 1,25-dihydroxyvitamin D₃ (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer.

  2012influential citation
• Synthesis and biological evaluation of a new vitamin D2 analogue.

  2012cites this paper
• Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer

  2012cites this paper
• Evaluation of efficacy, safety and tolerability of high dose-intermittent calcitriol supplementation to advanced intrahepatic cholangiocarcinoma patients--a pilot study.

  2012cites this paper
• Molecular Biology of Vitamin D Metabolism and Skin Cancer

  2011cites this paper
• Novel alkynylphosphonate analogue of calcitriol with potent antiproliferative effects in cancer cells and lack of calcemic activity.

  2011cites this paper
• Vitamin D3 enhances the apoptotic response of epithelial tumors to aminolevulinate-based photodynamic therapy.

  2011influential citation
• 1α,25-Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-β peptide(1-40) from mouse brain across the blood-brain barrier

  2011cites this paper
• A Phase I/II Clinical Trial of intravenous (IV) Calcitriol with fixed dose of Cisplatin and Docetaxel in Advanced Non-Small Cell Lung Cancer. Principal Investigator:

  2010cites this paper
• Vitamin D: Considerations in the Continued Development as an Agent for Cancer Prevention and Therapy

  2010cites this paper
• Prevalence of Overactive Bladder, its Under-Diagnosis, and Risk Factors in a Male Urologic Veterans Population

  2010cites this paper
• Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs

  2010influential citation
• Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.

  2010cites this paper
• pigenetic silencing of CYP 24 in the tumor microenvironment

  2010cites this paper
• Vitamin D in combination cancer treatment

  2010cites this paper
• CYP24A1 inhibition enhances the antitumor activity of calcitriol.

  2010cites this paper
• An immunohistochemical study of vitamin D receptor expression in canine cutaneous mast cell tumours.

  2010cites this paper
• The role of vitamin D in cancer prevention and treatment.

  2010cites this paper
• The full-length calcium-sensing receptor dampens the calcemic response to 1alpha,25(OH)2 vitamin D3 in vivo independently of parathyroid hormone.

  2009cites this paper
• A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors

  2009influential citation
• In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors

  2008influential citation
• Calcitriol is a potent inhibitor of retinal neovascularization.

  2007cites this paper
• Vitamin D signalling pathways in cancer: potential for anticancer therapeutics

  2007cites this paper
• A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors

  2007cites this paper
• Phase II trial of high‐dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen‐independent prostate cancer

  2006cites this paper
• Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer

  2005cites this paper
• Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation

  2005cites this paper
• CHAPTER 97 – Clinical Development of Calcitriol and Calcitriol Analogs in Oncology: Progress and Considerations for Future Development*

  2005cites this paper
• Anti-tumor activity of calcitriol: pre-clinical and clinical studies.

  2004cites this paper